Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical

Hepatology

Volumn 42, Issue 5, 2005, Pages 1206-1207

  Ghanta, Ravi K ^a   Mullen, Kevin D ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMMONIA; GLUCOSE;

AMMONIA BLOOD LEVEL; CLINICAL TRIAL; GLUCOSE BLOOD LEVEL; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERGLYCEMIA; INTELLIGENCE; LIVER FUNCTION; MEDICAL ETHICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL;

EID: 30944450666     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20946     Document Type: Note

References (4)

1. Uribe M, Moran S, Poo JL, Mendez-Sanchez L, Guevara L, Garcia-Ramos G. Beneficial effect of carbohydrate maldigestion induced by disaccharidase inhibitor (AO-128) in the treatment of chronic portal systemic encephalopathy. Scan J Gastroenterol 1998;33:1099-1106.
2. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998. HEPATOLOGY 2002;35:716-721.
3. Blei AT, Cordoba J. Hepatic Encephalopathy. Am J Gastroenterol 2001; 96:1968-1976.
4. Sanaka MR, Ong JP, Mullen KD. Challenges of designing hepatic encephalopathy treatment trials. HEPATOLOGY 2003:38;527-528.